We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthcare innovators don’t always come with flashy headlines, but the companies quietly reshaping how employers manage care costs can become some of the market’s strongest long-term winners. That’s exactly what makes Progyny (PGNY - Free Report) ) stock intriguing at around $23 a share.
Progyny has carved out a leadership position in fertility and family-building benefits, helping employers provide comprehensive fertility treatment coverage while improving clinical outcomes and lowering wasteful healthcare spending. As fertility care moves further into the mainstream and employers increasingly compete for talent through expanded healthcare benefits, Progyny sits directly in the middle of a rapidly growing secular trend.
The Expanding Fertility Services Market
The fertility services market has been expanding steadily over the past decade, fueled by rising infertility rates, delayed parenthood, greater social normalization of fertility treatments, and accelerating corporate adoption of fertility benefits. At the same time, investment in fertility clinics, reproductive technologies, and care infrastructure continues to increase globally, creating a powerful tailwind for companies operating in the space.
That growth opportunity is substantial. Industry forecasts project the global fertility services market could approach $70 billion by 2030, up dramatically from levels seen just a few years ago.
The chart below illustrates the strong projected expansion across every major geographic region through the end of the decade.
Image Source: Grand View Research
Why Progyny Stands Out
Unlike traditional insurance carriers, Progyny offers a specialized fertility benefits platform that combines smart benefit design, a curated provider network, pharmacy management, and patient advocacy services.
This model creates several advantages:
Better clinical outcomes
Lower multiple-birth complications
Reduced healthcare waste
Higher employee satisfaction
Stronger retention for employer clients
Employers increasingly view fertility coverage not as a niche perk, but as a strategic recruiting and retention tool. In a competitive labor environment, comprehensive fertility and family-building benefits can materially improve employee satisfaction and workforce loyalty.
That trend has driven growing adoption among Fortune 500 companies and large self-insured employers.
A Massive Secular Tailwind
The broader fertility market continues to benefit from several long-term demographic and social shifts:
Couples are waiting longer to start families
Infertility diagnoses continue rising globally
Awareness and acceptance of fertility treatment have increased
LGBTQ+ family-building demand continues to expand
Corporate healthcare benefit offerings are becoming more comprehensive
Meanwhile, advances in reproductive medicine and growing investment in fertility infrastructure are making treatments more accessible and effective.
For Progyny, these trends create a long runway for continued member growth and client expansion.
Progyny’s Reasonable Valuation & Steady Growth
Even with macro uncertainty affecting parts of the healthcare sector, Progyny has continued to generate strong revenue growth and healthy profitability metrics relative to many healthcare services peers.
The company’s asset-light platform model also provides scalability advantages as adoption of fertility treatment increases, and Progyny stock is reasonably valued at 11X forward earnings and less than 2X forward sales.
Furthermore, Progyny’s earnings outlook has continued to improve, helping fuel growing bullish sentiment around the stock and contributing to its current Zacks Rank #1 (Strong Buy) rating.
Analysts now expect PGNY to earn $1.94 per share in fiscal 2026 and $2.16 in 2027, representing projected annual EPS growth of 2.7% this year and more than 11% next year.
The most encouraging signal comes from the positive trend in earnings estimate revisions over the last 60 days, with FY26 and FY27 EPS estimates up roughly 2% respectively.
This comes as Progyny’s annual sales are expected to increase 7% this year and are projected to rise another 9% in FY27 to $1.51 billion.
Image Source: Zacks Investment Research
Bottom Line
Progyny offers investors exposure to one of healthcare’s fastest-growing specialty benefit categories. With fertility care demand rising globally, employers expanding coverage offerings, and demographic trends supporting long-term adoption, the company remains well-positioned to benefit from the continued evolution of reproductive healthcare.
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, PGNY deserves a close look.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Bull of the Day: Progyny (PGNY)
Healthcare innovators don’t always come with flashy headlines, but the companies quietly reshaping how employers manage care costs can become some of the market’s strongest long-term winners. That’s exactly what makes Progyny (PGNY - Free Report) ) stock intriguing at around $23 a share.
Progyny has carved out a leadership position in fertility and family-building benefits, helping employers provide comprehensive fertility treatment coverage while improving clinical outcomes and lowering wasteful healthcare spending. As fertility care moves further into the mainstream and employers increasingly compete for talent through expanded healthcare benefits, Progyny sits directly in the middle of a rapidly growing secular trend.
The Expanding Fertility Services Market
The fertility services market has been expanding steadily over the past decade, fueled by rising infertility rates, delayed parenthood, greater social normalization of fertility treatments, and accelerating corporate adoption of fertility benefits. At the same time, investment in fertility clinics, reproductive technologies, and care infrastructure continues to increase globally, creating a powerful tailwind for companies operating in the space.
That growth opportunity is substantial. Industry forecasts project the global fertility services market could approach $70 billion by 2030, up dramatically from levels seen just a few years ago.
The chart below illustrates the strong projected expansion across every major geographic region through the end of the decade.
Image Source: Grand View Research
Why Progyny Stands Out
Unlike traditional insurance carriers, Progyny offers a specialized fertility benefits platform that combines smart benefit design, a curated provider network, pharmacy management, and patient advocacy services.
This model creates several advantages:
Employers increasingly view fertility coverage not as a niche perk, but as a strategic recruiting and retention tool. In a competitive labor environment, comprehensive fertility and family-building benefits can materially improve employee satisfaction and workforce loyalty.
That trend has driven growing adoption among Fortune 500 companies and large self-insured employers.
A Massive Secular Tailwind
The broader fertility market continues to benefit from several long-term demographic and social shifts:
Meanwhile, advances in reproductive medicine and growing investment in fertility infrastructure are making treatments more accessible and effective.
For Progyny, these trends create a long runway for continued member growth and client expansion.
Progyny’s Reasonable Valuation & Steady Growth
Even with macro uncertainty affecting parts of the healthcare sector, Progyny has continued to generate strong revenue growth and healthy profitability metrics relative to many healthcare services peers.
The company’s asset-light platform model also provides scalability advantages as adoption of fertility treatment increases, and Progyny stock is reasonably valued at 11X forward earnings and less than 2X forward sales.
Furthermore, Progyny’s earnings outlook has continued to improve, helping fuel growing bullish sentiment around the stock and contributing to its current Zacks Rank #1 (Strong Buy) rating.
Analysts now expect PGNY to earn $1.94 per share in fiscal 2026 and $2.16 in 2027, representing projected annual EPS growth of 2.7% this year and more than 11% next year.
The most encouraging signal comes from the positive trend in earnings estimate revisions over the last 60 days, with FY26 and FY27 EPS estimates up roughly 2% respectively.
This comes as Progyny’s annual sales are expected to increase 7% this year and are projected to rise another 9% in FY27 to $1.51 billion.
Image Source: Zacks Investment Research
Bottom Line
Progyny offers investors exposure to one of healthcare’s fastest-growing specialty benefit categories. With fertility care demand rising globally, employers expanding coverage offerings, and demographic trends supporting long-term adoption, the company remains well-positioned to benefit from the continued evolution of reproductive healthcare.
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, PGNY deserves a close look.